Infliximab-related weight gain in inflammatory bowel disease: associations and financial impacts

Patricia Kaazan, Zhi Tan, Jana Bednarz, Julie Hughes, Rachel Grafton, Jane M. Andrews

Research output: Contribution to journalArticlepeer-review


Association between tumour necrosis alpha inhibitors and weight gain has been reported. We examined weight change in our cohort of inflammatory bowel disease patients treated with infliximab (IFX) for over 12 months, its associations and financial implications. Two-thirds of patients gained weight during the course of therapy. The mean change in weight after 12 months of IFX therapy was 3.3 (±6.5) kg.

Original languageEnglish
Pages (from-to)1134-1138
Number of pages5
JournalInternal Medicine Journal
Issue number9
Publication statusPublished or Issued - 1 Sep 2020
Externally publishedYes

ASJC Scopus subject areas

  • Internal Medicine

Cite this